Actively Recruiting
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Led by Fudan University · Updated on 2024-01-18
66
Participants Needed
1
Research Sites
154 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Based on different subtypes, subjects will be placed in one of three treatment groups to explore individual efficacy and safety of various treatment regimen.
CONDITIONS
Official Title
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 to 75 years
- Histologically or cytologically confirmed unresectable or metastatic clear cell carcinoma of the kidney, possibly with sarcomatoid lesions
- At least one measurable target lesion per RECIST 1.1 criteria
- Available tissue samples for testing
- No prior systemic treatment for the disease
- Eastern Cooperative Oncology Group performance status 0-1
- Normal major organ function within 14 days prior to enrollment, including specified blood counts and liver/kidney function
- Expected survival of 3 months or more
- Use of contraception if of potential fertility
- Signed informed consent to participate in the study
You will not qualify if you...
- Received radiation, surgery, chemotherapy, immunotherapy, or targeted therapy within 4 weeks prior to treatment
- Participation in other clinical drug studies within 4 weeks prior to treatment
- History of live attenuated vaccine within 4 weeks prior to treatment
- Prior treatment with PD-1/PD-L1 or CTLA-4 antibodies or other immunotherapy
- Prior targeted therapy
- Definite brain or meningeal metastasis
- Systemic corticosteroid or immunosuppressive therapy within 14 days prior to enrollment
- Active autoimmune disease or history of autoimmune disease, or history of allogeneic transplantation
- Severe adverse events within 4 weeks prior to study drug administration
- Active pulmonary infection or inflammation within 14 days prior to study drug
- Clinically significant bleeding or bleeding tendency within 3 months, or thrombosis within 6 months prior to treatment
- Active cardiovascular disease within 6 months prior to treatment
- Other malignancies in past 5 years except certain skin or in situ carcinomas
- Conditions affecting oral medication intake
- Active tuberculosis
- HIV positive or active hepatitis B or C infection
- Allergy to study drugs or severe reactions to monoclonal antibodies
- Pregnant or lactating women, or women not using reliable contraception
- Any medical condition endangering safety or study completion as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, China
Actively Recruiting
Research Team
D
dingwei ye
CONTACT
H
hailiang zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here